WallStreetZenWallStreetZen

NASDAQ: SION
Sionna Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SION

Based on 6 analysts offering 12 month price targets for Sionna Therapeutics Inc

Min Forecast
$24.00-43.03%
Avg Forecast
$45.17+7.21%
Max Forecast
$60.00+42.42%

Should I buy or sell SION stock?

Based on 6 analysts offering ratings for Sionna Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
1 analysts 16.67%
Strong Sell
0 analysts 0%
Although SION's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SION as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SION stock forecasts and price targets.

SION stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-14
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-12-01
lockedlocked$00.00+00.00%2025-10-17
lockedlocked$00.00+00.00%2025-09-08
Raymond James
Top 28%
73
Strong BuyInitiates Coverage On$45.00+6.81%2025-09-03

1 of 1

Forecast return on equity

Is SION forecast to generate an efficient return?

Company
-44.13%
Industry
355.57%
Market
202.3%
SION's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SION forecast to generate an efficient return on assets?

Company
-41.84%
Industry
123.33%
SION is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SION earnings per share forecast

What is SION's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$2.30
Avg 2 year Forecast
-$2.55
Avg 3 year Forecast
-$2.70

SION revenue forecast

What is SION's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$3.8M
Avg 3 year Forecast
$5.1M

SION vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SION$42.13$45.17+7.21%Strong Buy
ZLAB$17.20$52.00+202.33%Strong Buy
ARDX$7.86$14.67+86.60%Strong Buy
AUPH$14.57$17.25+18.39%Buy
NRIX$17.87$30.13+68.58%Strong Buy
View Top Biotech Stocks

Sionna Therapeutics Stock Forecast FAQ

Is Sionna Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: SION) stock is to Strong Buy SION stock.

Out of 6 analysts, 4 (66.67%) are recommending SION as a Strong Buy, 1 (16.67%) are recommending SION as a Buy, 0 (0%) are recommending SION as a Hold, 1 (16.67%) are recommending SION as a Sell, and 0 (0%) are recommending SION as a Strong Sell.

If you're new to stock investing, here's how to buy Sionna Therapeutics stock.

What is SION's earnings growth forecast for 2026-2028?

(NASDAQ: SION) Sionna Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.

Sionna Therapeutics's earnings in 2026 is -$70,676,000.On average, 11 Wall Street analysts forecast SION's earnings for 2026 to be -$102,574,806, with the lowest SION earnings forecast at -$136,894,344, and the highest SION earnings forecast at -$81,068,193. On average, 10 Wall Street analysts forecast SION's earnings for 2027 to be -$113,972,999, with the lowest SION earnings forecast at -$149,577,846, and the highest SION earnings forecast at -$74,507,762.

In 2028, SION is forecast to generate -$120,631,614 in earnings, with the lowest earnings forecast at -$163,136,072 and the highest earnings forecast at -$70,290,341.

What is SION's revenue growth forecast for 2026-2028?

(NASDAQ: SION) Sionna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.

Sionna Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast SION's revenue for 2026 to be $0, with the lowest SION revenue forecast at $0, and the highest SION revenue forecast at $0. On average, 10 Wall Street analysts forecast SION's revenue for 2027 to be $170,705,114, with the lowest SION revenue forecast at $0, and the highest SION revenue forecast at $1,405,806,822.

In 2028, SION is forecast to generate $227,606,819 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,405,806,822.

What is SION's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SION) forecast ROA is -41.84%, which is lower than the forecast US Biotechnology industry average of 123.33%.

What is SION's Price Target?

According to 6 Wall Street analysts that have issued a 1 year SION price target, the average SION price target is $45.17, with the highest SION stock price forecast at $60.00 and the lowest SION stock price forecast at $24.00.

On average, Wall Street analysts predict that Sionna Therapeutics's share price could reach $45.17 by Jan 14, 2027. The average Sionna Therapeutics stock price prediction forecasts a potential upside of 7.21% from the current SION share price of $42.13.

What is SION's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SION) Sionna Therapeutics's current Earnings Per Share (EPS) is -$4.67. On average, analysts forecast that SION's EPS will be -$2.30 for 2026, with the lowest EPS forecast at -$3.07, and the highest EPS forecast at -$1.82. On average, analysts forecast that SION's EPS will be -$2.55 for 2027, with the lowest EPS forecast at -$3.35, and the highest EPS forecast at -$1.67. In 2028, SION's EPS is forecast to hit -$2.70 (min: -$3.66, max: -$1.58).

What is SION's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SION) forecast ROE is -44.13%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.